Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ATHERO_MASS

Financiado

Cerrado

Identification of phospholipid Apo B adducts in atherosclerosis by a mass spectr...

Identification of phospholipid Apo B adducts in atherosclerosis by a mass spectrometry approach Atherosclerosis is a chronic inflammatory response, clinically asymptomatic in the first decade. The deposition of lipids in arterial walls, due to the uptake of oxidized low density lipoproteins (oxLDL) by macrophages, causes blo... ver más

31/10/2012

ASTON U

173K€

Presupuesto del proyecto: 173K€

Líder del proyecto

ASTON UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2012-10-31 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

ASTON U

0.00€ | Lider

UNIVERSITY OF STRATHCLYDE

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ProteoLipidomics1 Proteolipidomic characterization of the regulatory circuitry... 221K€ Cerrado

CardioBioLip Novel mass spectrometry based integrated analytical platform... 176K€ Cerrado

MASSTRPLAN MASS Spectrometry TRaining network for Protein Lipid adduct... 4M€ Cerrado

Athero-Flux Targeting novel lipid pathways for treatment of cardiovascul... 8M€ Cerrado

CHANCE Structure guided inhibition of IDOL to treat atherosclerosis... 150K€ Cerrado

TransCard Translating disease to cardiovascular health 8M€ Cerrado

Líder del proyecto

ASTON UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 173K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Atherosclerosis is a chronic inflammatory response, clinically asymptomatic in the first decade. The deposition of lipids in arterial walls, due to the uptake of oxidized low density lipoproteins (oxLDL) by macrophages, causes blood flow restriction making cardiovascular diseases (CVD) a serious public health problem in EU countries. In oxLDL, oxidation of (phospho)lipids and proteins occurs, originating phospholipids-protein adducts by cross-linking reactions. Though phospholipid-protein adducts were identified in atherosclerotic plaques by immunoassays, their structural features were not yet described. It is known that smaller and denser (SD) oxLDL is more atherogenic, but the mechanism is yet unclear. Improved understanding of the pathology and potential therapies depends on molecular characterization of atherogenic LDL particles including the phospholipid-Apo B (PL-Apo B) adducts. To achieve this, mass spectrometry based strategies will be used to characterize PL-Apo B adducts in SD oxLDL from healthy and diseased clinical samples. The methodological approach will be developed in control LDL in vitro oxidized (HOCl, MPO, Me+H2O2) to determine the nature of PL-Apo B adducts formed, followed by biotinylation and separation by avidin magnetic beads of PL-Apo B adducts for optimization of PL-Apo B adducts isolation protocols with high specificity and sensitivity. Detection through MS strategies (MRM, CID) avoids time consuming analysis by a focused detection approach. Subsequently, the optimized approach will be applied to LDL from clinical samples in search of PL-Apo B adducts. The data from clinical samples will be scrutinized by chemometric techniques for discriminant ions prior to full characterization. This study will contribute to the molecular understanding of CVD pathology. The development of advanced methods for routine analysis will enable identification of new biomarkers for early clinical diagnosis.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores